NEW
YORK, June 16, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
today announced that the Company will participate in a fireside
chat at the Maxim Healthcare Virtual Conference on Wednesday, June 21, 2023 at 12:30 PM EST.
This conference will be webcast live on M-Vest. Sign up
here to attend.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing targeted radiotherapies
to deliver cancer-killing radiation with cellular level precision
to treat patients with high unmet needs. Actinium's clinical
pipeline is led by targeted radiotherapies that are being applied
to targeted conditioning, which is intended to selectively deplete
a patient's disease or cancer cells and certain immune cells prior
to a bone marrow transplant (BMT), gene therapy or adoptive cell
therapy, such as CAR-T, to enable engraftment of these transplanted
cells with minimal toxicities. Our lead product candidate, Iomab-B
(I-131 apamistamab) has been studied in over four hundred patients,
including the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed
or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT
conditioning. The SIERRA trial was positive with Iomab-B meeting
the primary endpoint of durable Complete Remission of 6-months with
high statistical significance (p<0.0001). Iomab-B enabled 100%
of patients to access a BMT and produced higher rates of post-BMT
CR. Iomab-B produced positive results for the secondary endpoints
of the SIERRA trial including reducing the probability of an event
by 78% resulting in an Event-Free Survival (EFS) Hazard Ratio of
0.22 (p<0.0001), doubled 1-year overall survival and median
overall survival. Iomab-ACT, low dose I-131 apamistamab, is being
studied as a targeted conditioning agent in a Phase 1 study with a
CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center
with NIH funding. Actimab-A, our second most advanced product
candidate has been studied in approximately 150 patients with Acute
Myeloid Leukemia or AML, including in combination trials with the
chemotherapy regimen CLAG-M and with venetoclax, a targeted
therapy. Actimab-A or lintuzumab-Ac225 is an Actinium-225 based
antibody radiation conjugate targeting CD33, a validated target in
AML. Actinium has entered into a Cooperative Research and
Development Agreement (CRADA) with the National Cancer Institute
(NCI) to develop Actimab-A as a single agent or combination with
chemotherapy, targeted agents or immunotherapy in Phase 1, 2 or 3
trials. The NCI will fund clinical trial expenses under the CRADA
while Actinium will supply Actimab-A. The NCI is currently
accepting proposals for non-clinical and clinical studies with
Actimab-A. Actinium is a pioneer and leader in the field of
Actinium-225 alpha therapies with an industry leading technology
platform comprising over 200 patents and patent applications
including methods of producing the radioisotope AC-225. Our
technology and expertise have enabled collaborative research
partnerships with Astellas Pharma, Inc. for solid tumor
theranostics, with AVEO Oncology Inc. to create an Actinium-225
HER3 targeting radiotherapy for solid tumors, and with EpicentRx,
Inc. to create targeted radiotherapy combinations with their novel,
clinical stage small molecule CD47-SIRPα inhibitor. More
information is available on Actinium's website:
https://www.actiniumpharma.com/.
Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-to-present-at-the-maxim-healthcare-virtual-conference-301852583.html
SOURCE Actinium Pharmaceuticals, Inc.